The purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of SH D00342A. Subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
840
Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
Unnamed facility
Hanover, Lower Saxony, Germany
Unnamed facility
Dresden, Saxony, Germany
Unadjusted Pearl Index
Time frame: After 13 cycles of intake
Adjusted Pearl Index
Time frame: After 13 cycles of intake
Cumulative pregnancy rate
Time frame: After 13 cycles of intake
Bleeding pattern
Time frame: After 13 cycles of intake
Cycle control
Time frame: After 13 cycles of intake
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Dresden, Saxony, Germany
Unnamed facility
Dresden, Saxony, Germany
Unnamed facility
Dresden, Saxony, Germany
Unnamed facility
Großpösna, Saxony, Germany
Unnamed facility
Leipzig, Saxony, Germany
Unnamed facility
Leipzig, Saxony, Germany
Unnamed facility
Leipzig, Saxony, Germany
Unnamed facility
Aschersleben, Saxony-Anhalt, Germany
...and 15 more locations